ABSTRACT
The link between atrial fibrillation (AF) and stroke has gained attention due to AF’s significant impact on stroke risk. Detecting AF, especially paroxysmal AF, presents challenges, highlighting the necessity for continuous Holter monitoring. In our investigation, we utilized commercial data archives to examine AF prevalence and associated cardiac arrhythmias among stroke patients and controls. We also analyzed various factors, such as age, gender, symptoms, test duration, and duration post-stroke, to identify predictors of arrhythmias and enhance paroxysmal detection rates. We included 98 stroke patients and 98 controls for comparing AF prevalence within 72 hours post-stroke and analyzed 779 stroke patients within 4 days to 10 weeks post-stroke. Our findings revealed a higher AF detection rate in stroke patients compared to controls, with AF being the most prevalent arrhythmia observed. Older age and symptom presence were associated with significant findings, particularly AF. Temporal analysis showed a negative correlation between AF and complete heart block occurrence over time, while ventricular tachycardia exhibited a positive correlation. Paroxysmal fibrillation detection rates were highest within the initial month, with the optimal duration of Holter monitoring being 10 days, underscoring the importance of extended monitoring for detecting paroxysmal atrial fibrillation. Detecting paroxysmal atrial fibrillation could influence stroke management. Furthermore, our study suggests the potential utility of commercial data in yielding comparable outcomes to research data.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding for this study was provided by Cardioscan Pye Ltd. The role of the funder was solely in financial support and did not extend to study design, data collection, analysis, interpretation, or manuscript preparation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study adhered to the principles outlined in the Declaration of Helsinki. Patient privacy and confidentiality were safeguarded through the deidentification of patient records, and no interventions were administered to eliminate ethical concerns.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript